The colonization with Candida species is more harmful in the second trimester of pregnancy by Iris Holzer et al.
Vol.:(0123456789) 
Arch Gynecol Obstet (2017) 295:891–895 
DOI 10.1007/s00404-017-4331-y
MATERNAL-FETAL MEDICINE
The colonization with Candida species is more harmful 
in the second trimester of pregnancy
Iris Holzer1 · Alex Farr1 · Herbert Kiss1 · Michael Hagmann2 · Ljubomir Petricevic1 
Received: 11 January 2017 / Accepted: 10 February 2017 / Published online: 3 March 2017 
© The Author(s) 2017. This article is published with open access at Springerlink.com
of 3243 g, compared to 2989 g in the group with a second 
trimester colonization (p < 0.0001).
Conclusion Women who are colonized with Candida 
spp. during the second trimester of pregnancy have higher 
rates of preterm birth and lower neonatal birthweight than 
those who are colonized during the first trimester of their 
pregnancy. Screening programs for asymptomatic Candida 
colonization should take this information into account.
Keywords Vaginal smear · Candidosis · Candida 
colonization · Preterm birth · Birthweight
Introduction
Preterm birth (PTB) is defined as birth before 37 completed 
gestational weeks. Despite all efforts in modern maternity 
care, PTB remains one of the most fundamental challenges 
in obstetrics, and the leading cause of neonatal morbidity 
and mortality [1]. Preterm neonates are at an increased risk 
for a wide range of adverse neonatal outcomes, in addition 
to the burden of considerable economic consequences that 
they cause for affected families and health services [2]. 
Although PTB is considered a multi-factorial event, vaginal 
infections remain the major associated factor in up to 40% 
of all cases with PTB [3–5].
According to Leli et al. [6], the colonization with Can-
dida spp. occurs more frequently in pregnant compared to 
non-pregnant women (31.4 vs. 19.9%). In particular, preg-
nant women are more often suffering from asymptomatic 
Candida spp. colonization than their non-pregnant coun-
terparts (46.5 vs. 16.0%) [6]. Apart from bacterial vagi-
nosis, which has extensively been studied for its effect on 
pregnancy outcomes, there is evidence that even an aerobic 
bacterial infection during pregnancy should be treated to 
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significantly improve perinatal outcomes [7]. The data on 
the effect of the antenatal vaginal colonization with Can-
dida are still limited [3, 6]. Cotch and colleagues found no 
association of candidosis with low birthweight and PTB 
[8]. In contrary, our recently published data demonstrated 
that the recurrent asymptomatic vaginal colonization with 
Candida spp. in early pregnancy is indeed associated with 
PTB and low birthweight [9]. This stands in accordance 
with the results of a study that reported a reduction in spon-
taneous PTB among women with asymptomatic coloniza-
tion of Candida spp. who were treated with clotrimazole 
[10].
Essentially, these results indicate that screening pro-
grams for the asymptomatic vaginal colonization with 
Candida spp. could be of value. However, more data about 
the ideal time-point and setting of screening programs are 
needed. To date, it remains unclear whether the primary 
colonization with Candida during the first or second tri-
mester of pregnancy is more harmful. Our study is the 
first to evaluate the impact of the trimester of vulvovagi-
nal candidosis in terms of pregnancy outcomes and PTB in 
particular.
Patients and methods
Between 1 January 2005 and 1 January 2014, data from all 
women with singleton pregnancies, who were diagnosed 
with the vaginal colonization of Candida spp. at the Medi-
cal University of Vienna, Department of Obstetrics and 
Gynecology, were retrospectively analyzed. We considered 
vaginal smears of both symptomatic and asymptomatic 
women, who had a first-time Candida colonization during 
their first or second trimester of pregnancy. Eligible women 
had singleton pregnancies and registered for a planned 
birth at our obstetrical center. All of them were antenatally 
diagnosed with Candida spp. on the basis of their vaginal 
smears, which were undertaken either during the first or 
second trimester of pregnancy. Women with bacterial vagi-
nosis, intermediate vaginal flora or other bacterial infec-
tions were excluded from the analyses. The standard treat-
ment for Candida vulvovaginitis was local clotrimazole 
0.1 g for 6 days within 3–5 days after diagnosis.
The cut-off between the first and second trimester of 
pregnancy was determined at 14 + 0  gestational weeks 
with the second trimester being defined as the gestational 
age between 14 + 0 and 28 + 6 weeks. Study group 1 con-
sisted of women, who were primarily diagnosed with Can-
dida colonization or candidosis during the first trimester, 
whereas Study group 2 consisted of women, who were pri-
marily diagnosed with Candida colonization or candidosis 
during the second trimester of their pregnancy. Pregnancy 
outcomes were assessed on the basis of gestational age at 
birth, recorded as term birth at or later than 37 + 0 gesta-
tional weeks. PTB was defined as the spontaneous birth 
at or less than 36 + 6 gestational weeks. The rate of PTB 
served as the primary outcome measure. Secondary out-
come measures included neonatal birthweight and the neo-
natal Apgar score. Stillbirth was defined as the term or pre-
term birth of a neonate that had died in utero and was born 
with an Apgar score of 0/0/0.
The demographic and background information was sum-
marized and displayed using descriptive statistics. Discrete 
data are presented as N (%). The Chi-squared test was used 
to compare groups of categorical data. For comparison of 
continuous data, Welch’s t test was used. A two-sided p 
value <0.05 was considered statistically significant. Logis-
tic and linear regression was used to determine the adjusted 
effect of variables. A multiple regression model was con-
ducted that included the following potentially confound-
ing variables that were unequally distributed between the 
groups and that were compared and considered to have 
an impact on the end-point: maternal age, tertiary educa-
tion, history of PTB and nicotine abuse. All relevant data 
were collected from obstetric databases, patient charts and 
microbiologic reports.
Results
Retrospective data analysis identified a total of 1066 
women with singleton pregnancies, who were antenatally, 
and for the first time, diagnosed with asymptomatic and/
or symptomatic Candida spp. on the basis of their vaginal 
smears, during the first or second trimester of their preg-
nancy. Out of these women, 673 (63%) women were diag-
nosed with Candida spp. during the first trimester, and 393 
(37%) women were diagnosed during the second trimester 
of pregnancy. Overall, mean maternal age at the time of 
birth was 30.2 ± 6.3 years. Table 1 illustrates the baseline 
variables, sociodemographic characteristics and obstetri-
cal history of the included study participants. No serious 
adverse events were reported for the treatment that was 
subsequently initiated.
In the overall study cohort, the mean gestational age at 
birth was 38.5 ± 3.0 weeks, corresponding to a mean birth-
weight of 3144 ± 694  g. In women of study group 1, the 
mean gestational age at birth was 38.9 ± 2.3 weeks, and in 
those of study group 2, it was 37.8 ± 3.9 gestational weeks. 
Infants of women in study group 1 had a mean birthweight 
of 3234 ± 600  g, compared to a mean of 2989 ± 810  g in 
those who were assigned to study group 2 (p < 0.0001). In 
study group 1, the rate of PTB was 10% (N = 64), compared 
to 18% (N = 71) in study group 2 (p = 0.0002). This was 
confirmed in a multiple regression model after adjustment 
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for nicotine abuse as the only remaining significant 
confounder.
The mean Apgar scores at 1 min were significantly dif-
ferent for neonates of women of study group 1 vs. those of 
study group 2 (8.7 ± 1.0 vs. 8.4 ± 1.6; p = 0.0004). Table 2 
summarizes the pregnancy outcomes of the 1066 study par-
ticipants with Candida colonization.
Discussion
The present study was undertaken to evaluate the impact of 
the trimester of Candida colonization with regard to preg-
nancy outcomes. As it is known that the recurrent asymp-
tomatic colonization with Candida is involved in the mul-
tifactorial event of PTB, we now wanted to evaluate the 
impact of vaginal colonization or infection with Candida 
spp. on subsequent pregnancy outcomes. This information 
could help to determine the ideal time-point for a routine 
antenatal infection-screening program.
It has already been demonstrated that routine antenatal 
infection-screening programs have the potential to reduce 
the rates of PTB and late miscarriage in a general popu-
lation of pregnant women [1]. For this reason, our depart-
ment has integrated a program for all pregnant women, to 
screen and treat for the asymptomatic colonization with 
pathogens, including bacterial vaginosis and vaginal candi-
dosis [11]. As it is known that recurrent vulvovaginal can-
didosis can be harmful during early pregnancy, the need for 
early detection and adequate antifungal treatment is clearly 
emphasized [10].
A recently published review reported that the use of 
locally delivered dequaliniumchloride led to a complete 
cure in 84% of the pregnant women with Candida [12]. 
Another treatment of vaginitis in pregnancy is octenidine 
dihydrochloride/phenoxyethanol that has shown a positive 
effect in women with bacterial vaginosis and/or candidosis 
[13]. More easily, screening strategies prior to any infection 
could help balancing the health care budget, as shown in 
a cost-effectiveness analysis [14]. The costs per prevented 
PTB or pregnant woman screened amounted to merely 7% 
of the direct costs saved as a result of screening. Indeed, 
PTB incurs notable social and healthcare costs, particularly 
in European countries with national health care systems 
Table 1  Baseline variables 
of the 1066 study participants 
with Candida colonization or 
candidosis
PTB preterm birth, SD standard deviation, N number
Variable Baseline variables (N = 1066) All
Study group, trimester 1 Study group, trimester 2
Mean ± SD, N (%) Mean ± SD, N (%) Mean ± SD, N (%)
Participants 673 (63) 393 (37) 1066 (100)
Age at birth (years) 30.4 ± 6.0 29.8 ± 6.6 30.2 ± 6.3
Nicotine abuse 144 (21) 106 (27) 250 (23)
Academic education 45 (7) 34 (9) 23 (9.7)
History of PTB 9 (1) 9 (2) 18 (2)
Table 2  Obstetric outcomes of the 1066 study participants with Candida colonization or candidosis
N number, SD standard deviation, NS not significant
Variable Category/unit Study group (N = 1066) All Test
Trimester 1 Trimester 2
Mean ± SD, N (%) Mean ± SD, N (%) Mean ± SD, N (%) p value
Pregnancy outcome Live birth 672 (100) 388 (99) 1060 (99) NS
Stillbirth 1 (0) 5 (1) 6 (1)
Prematurity Preterm birth 64 (10) 71 (18) 135 (13) 0.0002
No preterm birth 609 (90) 322 (82) 931 (87)
Apgar at 1 min Score 8.7 ± 1.0 8.4 ± 1.6 8.6 ± 1.3 0.0004
Apgar at 5 min Score 9.7 ± 0.9 9.4 ± 1.6 9.6 ± 1.2 NS
Apgar at 10 min Score 9.8 ± 1.1 9.6 ± 1.6 9.7 ± 1.3 NS
Gestational age at birth Weeks 38.9 ± 2.3 37.8 ± 3.9 38.5 ± 3.0 NS
Birthweight Grams 3234 ± 600 2989 ± 810 3144 ± 694 <0.0001
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and socialized medicine. The antenatal infection-screen-
ing program that we used in our study has been proven to 
reduce PTB rates by 50%, and therewith save these costs 
[14, 15].
In addition to the socioeconomic advantages, the high 
prevalence of Candida colonization guided us to integrate 
an antenatal infection-screening program during routine 
pregnancy care. Data showed that patients with recurrent 
candidosis during early pregnancy had higher rates of PTB 
[9]. In the present study, we only analyzed data of women, 
who were uniformly colonized or affected with Candida 
spp. and in this patient group, we found an overall PTB rate 
of 13%. This rate seems to be higher than the PTB rate in 
a large retrospective Hungarian study that shows a 4.6% 
rate of PTB in women, who were colonized with Candida 
spp. and treated with clotrimazole [16]. The reason for the 
higher PTB rate in our study might be that our study was 
conducted in the tertiary setting, including women with 
high-risk pregnancies and comorbidities that might inter-
fere with the susceptibility for vaginal candidosis. In con-
trast, the Hungarian study was a nationwide trial that con-
tained mostly data of women with low-risk pregnancies. A 
randomized controlled trial from Australia [17] reported 
a PTB rate of 4% in pregnant women with asymptomatic 
vaginal Candida colonization who were treated with clotri-
mazole. Considering the comparable PTB rates among 
Austrian and Australian women [18, 19], the 4% PTB rate 
among the Australian women with candidosis seems to 
be actually lower than that of our study. The prospective 
design of the Australian study could have led to the recruit-
ment and randomization of patients without other risks for 
PTB, since the authors of this study did not clearly list their 
exclusion criteria.
In 2008, a prospective study analyzed the prevalence 
of Candida spp. in pregnant women and reported that the 
highest colonization rate (65.7%) was found in women 
between 21 and 30 years of age [20]. The mean age in our 
study population was 30.2 years, which seems to be com-
parable on the basis of our tertiary setting. The mean birth-
weight of all our study participants with Candida colo-
nization was 3144 g at a mean gestational age at birth of 
38.5 gestational weeks. This seems to be comparable to the 
mean birthweight of 3330  g in the nationwide Hungarian 
trial [16]. Here, the authors reported a mean gestational 
age of 39.8  weeks at birth, which might be explained by 
the higher rate of cesarean sections in our tertiary referral 
center.
The main finding of our study was that the primary 
colonization with Candida spp. was more harmful in the 
second than in the first trimester of pregnancy. This find-
ing was highly statistically significant in a multiple regres-
sion model. In a large prospective study from Belgium, it 
was demonstrated that women with a normal vaginal flora 
in the first trimester of pregnancy had a 75% lower risk of 
preterm birth before 35 + 0 weeks of gestation, when being 
compared to women with an abnormal flora [21]. In the 
meanwhile, the PTB-risk increasing effect of bacterial vag-
inosis and recurrent Candida colonization during the first 
trimester of pregnancy was described [9]. The finding of 
our study, that the occurrence of Candida spp. during the 
second trimester of pregnancy also influences pregnancy 
outcomes, and that it is even more harmful during the sec-
ond trimester of pregnancy, has not yet been described in 
the literature. It seems to be of particular interest for the 
planning and organization of infection screening-programs 
aiming to detect vulvovaginal candidosis, even after first 
trimester of pregnancy.
According to a recent study on vulvovaginitis in preg-
nant women, only 7% of infections are occurring in the 
first, but 60% in the second trimester [22]. However, the 
data of this study included a variety of pathological condi-
tions, and not only the colonization with Candida. Theo-
retically, immunologic alternations during pregnancy could 
have contributed to the altered severity and susceptibility of 
pathogen colonization during pregnancy. Aspects of innate 
immunity are enhanced towards late pregnancy, so that this 
may contribute to an immune down-regulation of the physi-
ologic lower genital tract [23]. This could be one of the rea-
sons for the increased detection of vaginal infections during 
the second trimester of pregnancy. To prevent PTB, Rob-
erts et al. [17] decided to screen and treat for candidosis in 
the early to mid second trimester of pregnancy. We suggest 
that this is the ideal time-point for an antenatal infection-
screening program.
It should clearly be stated that our study has a number 
of limitations. Other factors that occurred after the screen-
ing could have contributed to the reported pregnancy out-
comes. Moreover, we did not distinguish between moderate 
and heavy colonization in our study, as Roberts et al. [17] 
did it in their large controlled trial. Furthermore, we were 
not able to perform PCR methods. We have to admit that 
this was not possible due to the retrospective design of our 
study, which clearly limits its value.
We are also aware that it would have been ideal to dif-
ferentiate between different Candida spp., as it was done 
in some previous studies [16, 17]. However, we know that 
C. albicans is the most frequent species in 80–90% of all 
women who suffer from candidosis [20].
Conclusion
In this study, we have demonstrated that women who are 
colonized with Candida spp. during the second trimester 
of pregnancy have higher rates of preterm birth and lower 
neonatal birthweight than those who are colonized during 
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the first trimester of their pregnancy. Despite all limita-
tions, our findings lend support to the idea that time-point 
of Candida diagnosis and treatment matters. As recurrent 
candidosis is known to increase the risk of PTB, our results 
indicate that the antenatal screening for Candida should 
ideally be performed during the early second trimester of 
pregnancy. We suggest there is a need for adequate infec-
tion screening programs in routine pregnancy care, which 
should take this information into account.
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